YuanBio Venture

The firm is physically headquartered inside Suzhou's bioBAY industrial park, which houses over 600 biotech companies. This co-location provides direct, early access to founders and spinouts emerging from the park's research infrastructure, giving YuanBio a proprietary sourcing channel not available to firms outside bioBAY.

YuanBio Venture invests across four primary verticals: novel drug discovery, medical devices, diagnostics and precision medicine, and healthcare services. The firm has built dedicated platform networks within each vertical to support portfolio companies with technical expertise and industry connections.

The firm invests from seed and start-up through expansion and late-stage growth, maintaining a stage-agnostic approach within the healthcare sector. This flexibility allows it to continue supporting portfolio companies from early development through pre-IPO rounds.

The firm reports over 200 portfolio investments and 19 companies that have listed on public markets, including the Hong Kong Stock Exchange and Shanghai's STAR Market (per the firm). Named public companies in its portfolio include PersonGen, ClinChoice, and Dymind.

YuanBio Venture operates from within bioBAY, Suzhou's major biotech industrial park, and leverages the park's infrastructure and tenant network as a core part of its investment strategy. bioBAY provides access to deal flow, post-investment operational support, and a collaborative ecosystem of entrepreneurs and researchers.

The firm's website lists a scientific and investment team that includes 林艺 (PhD, Columbia; MBA, Chicago), 陈杰 (MBA, Cornell), 高维鹏 (law degree, Peking University; EMBA, CEIBS), 班博, and 成岗. The firm does not publicly designate a single CIO or managing partner title, presenting the group as a collective of operator-investors.

The firm describes itself as 'rooted in bioBAY and radiating globally.' While its headquarters and primary focus remain on China's healthcare market, the firm's posture and advisor network suggest international co-investment and cross-border deal capability, though specific non-China investments are not publicly detailed.